{
    "organizations": [],
    "uuid": "749e82b4b765e5b9fb4c058946ac7248a8c03603",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-anaptysbio-qtrly-loss-per-share-03/brief-anaptysbio-qtrly-loss-per-share-0-30-idUSASB0C8UZ",
    "ord_in_thread": 0,
    "title": "BRIEF-AnaptysBio Qtrly ‍Loss Per Share $0.30",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 5 (Reuters) - AnaptysBio Inc:\n* ANAPTYSBIO ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND 2018 PIPELINE MILESTONES\n* QTRLY ‍LOSS PER SHARE $0.30 * ‍EXPECTS THAT ITS CASH, CASH EQUIVALENTS AND INVESTMENTS WILL FUND ITS CURRENT OPERATING PLAN THROUGH END OF 2019​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-06T06:11:00.000+02:00",
    "crawled": "2018-03-06T22:34:43.042+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "anaptysbio",
        "inc",
        "anaptysbio",
        "announces",
        "fourth",
        "quarter",
        "full",
        "year",
        "financial",
        "result",
        "pipeline",
        "milestone",
        "qtrly",
        "per",
        "share",
        "cash",
        "cash",
        "equivalent",
        "investment",
        "fund",
        "current",
        "operating",
        "plan",
        "end",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}